awaits
Huge prize awaits country that harnesses AI recruiting
- By Olivia Renshaw
- . May 6, 2025
[ad_1] Thank you to Sarah O’Connor for her bracing analysis of the appalling muddle of artificial intelligence in recruiting (“AI arms race in hiring is
Rare diseases policy awaits comprehensive implementation
- By Ethan Caldwell
- . April 6, 2025
[ad_1] The National Policy for Rare Diseases (NPRD) 2021 provides a comprehensive framework for the diagnosis and treatment of rare diseases. NPRD classifies rare diseases
Jes Staley awaits judgment in courtroom battle over ‘Uncle Jeffrey’ Epstein
- By Olivia Renshaw
- . April 5, 2025
[ad_1] At the end of four days of cross examination, Jes Staley stepped down from the witness stand and hugged his legal team. It had
Trump tariffs: Indian auto components subject to 25% import tariff in US, sector awaits detailed list
- By Ethan Caldwell
- . April 2, 2025
[ad_1] The Automotive Component Manufacturers Association of India (ACMA) on Thursday said it is waiting for the detailed list of auto components that will be
An anxious America awaits Donald Trump’s ‘reciprocal tariffs’
- By Olivia Renshaw
- . April 1, 2025
[ad_1] This is an on-site version of the White House Watch newsletter. You can read the previous edition here. Sign up for free here to get it
Crude oil futures drop as market awaits outcome of US-Russia talks
- By Ethan Caldwell
- . March 23, 2025
[ad_1] Crude oil futures traded lower on Monday morning as the US and Russian delegations are set to meet on Monday to discuss a ceasefire
UK comic book makers join forces as AI copycat battle awaits
- By Olivia Renshaw
- . March 23, 2025
[ad_1] Stay informed with free updates Simply sign up to the Media myFT Digest — delivered directly to your inbox. The makers of comic book
Cellogen Therapeutics awaits CDSCO nod for human trial on its ‘bi-specific 3rd generation’ CAR-T therapy
- By Ethan Caldwell
- . March 18, 2025
[ad_1] Biotech start-up Cellogen Therapeutics is awaiting a nod from the Central Drugs Standard Control Organisation (CDSCO) to start its first-in-human (Phase I) trials on